CDKN2A and cancer: Springer et al. [26] have also analyzed mutations in TERT promoter, mutations in FGFR3 in combination with other nine gen mutations (TP53, CDKN2A, ERBB2, HRAS, KRAS, PIK3CA, MET, VHL, MLL) plus detection of aneuploidy,an abnormal chromosome number, that has been estimated to be present in > 90% of the cancer of most histopathologic types [49].